FRUZAQLA (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
FRUZAQLA
Date registered
Evaluation commenced
Decision date
Approval time
165 (255 working days)
Active ingredients
fruquintinib
Registration type
NCE/ NBE
Indication
FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, and an anti-EGFR agent if appropriate.